# Adversarial review log — retatrutide-weight-loss

Authoring model: **Sol 6.1**. Adversarial reviewer: **Claude Opus 5.5 (Anthropic)**. Date: **2026-10-14**.
Canonical copy: `hsef_v53_traffic_first_five_2026-10-12/retatrutide-weight-loss/retatrutide-weight-loss.review.md`.

## Summary

| Item | Before | After |
|---|---|---|
| HSEF level | Ε — Context-specific causality established | Ε — Context-specific causality established (unchanged) |
| Confidence | Moderate | Moderate (unchanged) |
| Causal role | reinforcing / stabilizing factor | unchanged |
| Momentum / Stability / Divergence | Decisive work underway / Uncertain / Contested | unchanged |
| Validator | not previously emitted | PASS — 0 fail, 0 warn, 31 pass (`validator.txt`) |

Findings by severity: **Critical 0, Major 3, Minor 2, Editorial 1** (6 corrections applied).
PMIDs checked: **60/60 references verified, 0 failed**, plus 6 linked erratum notices confirmed as Published Errata.
Load-bearing claims spot-checked: **11, all accurately attributed**.

## Findings

| ID | Severity | Location | Correction |
|---|---|---|---|
| B1 | Major | Evidence card [57], decisive-perturbation entry [57], Consensus reconciliation, and the matching scorecard evidence rows | "selected-vial analytical/endotoxin concerns" understated the source: endotoxin was detected in all three delivered vials and measured purity was 7.7-14.37% against a 99% label claim. Now stated explicitly, with the point that two of the three endotoxin values are upper bounds retained. |
| B2 | Major | Throughout, ~140 sites | Pervasive builder rendering defect that glued whole words, not just numerals, including in the grey-market supply paragraph. Spacing restored; trial names normalised to hyphenated forms. No value, unit, identifier or claim direction changed. |
| B3 | Minor | Research timeline, 2023 entry | "dulagutide" → "dulaglutide". |
| B4 | Minor | Evidence cards, 6 sites | "ErratumIn: PMID…" → "Erratum in: PMID …". |
| B5 | Editorial | Decisive-experiment and status fields | Doubled field-separator full stops reduced to one. |
| B6 | Major | AT A GLANCE, "Best-supported rival" | The field named the nominal model (score card `is_nominal: true`, rank 1) as the best-supported rival, offering the hypothesis as its own leading rival. Now names the best-supported non-nominal model, GLP1-based appetite suppression at Ε, and states that the nominal still leads the tournament. Known renderer defect printing `models_evaluated[0]`; score card rank and nominal flags unchanged. |

## Rejected findings (checked, no change)

1. Ε rather than Ζ — the framework's own text ("three replications of one line make a confident Ε, not a Ζ") supports the level; mouse receptor work is not an independent line on the human clinical claim.
2. Ε as the headline — the central claim is itself registered to trial-eligible adults, so SC2's scope matches it.
3. Causal role at derivation step 5 — primary driver considered and rejected for want of retatrutide-specific withdrawal and rate-limitation evidence; derivation is written out.
4. Momentum "Decisive work underway" — artifact names the TRIUMPH registrational and outcomes programme.
5. 80-week results treated as corroboration outside the registered 24-72-week gate rather than redefining it. Correct.
6. SC4 at Α — the review neither claims grey-market vials are equivalent nor that they are uniformly dangerous; absence of evidence is explicitly distinguished from measurement. Consumer-safety framing checked in both directions.
7. No citation-year deviation beyond one year; no collective-author rendering defect in this reference list.
8. Confidence band Moderate — verified against the framework's confidence text rather than access depth. High requires extensive independent replication across labs, models and assay modalities; the retatrutide trials are one sponsor, one modality and, as the review itself argues, one causal line. Moderate is correct.
9. No false-approval or false-provenance clause is present, and no earlier adversarial approval is asserted.

## Files changed

- `retatrutide-weight-loss.review.md` — banner, `## ADVERSARIAL REVIEW AND APPROVAL`, B1–B6.
- `retatrutide-weight-loss.scorecard.json` — the two evidence rows carrying the card [57] text (B1).
- `validator.txt` — new; PASS.
- `sol61-original/` — pre-review copies of the review, scorecard and validation report.

No package-level file was edited.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved.
— Claude Opus 5.5 (Anthropic), 2026-10-14.